Clinical trials
Nicotine Use Disorder clinical trials
Below are recruiting nicotine use disorder clinical trials, each written for real people, not researchers. We’re tracking 154 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05011760RecruitingEarly Phase 1
PET brain scan with a cocaine-use disorder medicine test
This early-phase study uses a PET brain scan (a special imaging test) to see how the brain responds in people with cocaine use disorder. It aims to better understand brain activity and whether this scan approach could help research or future treatments.
Pittsburgh, PennsylvaniaAges 18–55 - NCT04066192RecruitingPhase 2
Brexpiprazole trial for alcohol use disorder in adults
This study tests whether brexpiprazole can help adults with alcohol use disorder. You must currently not be taking alcohol-focused treatment or alcohol medicines, and you’ll likely complete questionnaires and brain scans.
Aurora, ColoradoAges 21–65 - NCT03667846RecruitingPhase 2
Biomarker-guided treatment for drinking and PTSD symptoms
This Phase 2 study tests whether blood/brain “biomarkers” can help choose a treatment plan for people who have alcohol use disorder and PTSD. The goal is to improve outcomes related to drinking and PTSD symptoms compared with a standard approach.
New York, New YorkAges 18–70 - NCT03470480Recruiting
Brain stimulation for methamphetamine cravings
This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can help reduce cravings for methamphetamine in people who have stopped using it for at least 4 weeks. If you are trying to stay off methamphetamine and struggling with cravings, this treatment might help.
Portland, OregonAges 18–65 - NCT07568483Recruiting
Web-based smoking cessation support program
This study tests TUBSIS 2.0, a digital program designed to help you quit or cut back on smoking. You'll use it on your computer, tablet, or phone, and researchers will track how it affects your smoking habits over time.
ZurichAges 18 years+ - NCT07559500RecruitingPhase 1
Study of tirzepatide for alcohol use disorder
This trial tests if tirzepatide, a diabetes drug, affects brain chemistry linked to alcohol use. Researchers want to see if it can help people with mild-to-moderate alcohol use disorder who also have tried stimulants.
Bethesda, MarylandAges 21–65 - NCT07218354RecruitingPhase 3
Study of semaglutide to help veterans drink less alcohol
This study tests whether a weekly medicine called semaglutide can help veterans who drink heavily reduce their alcohol intake. If you're a veteran and want to cut down on drinking, this study may be an option.
Long Beach, CaliforniaAges 18–80 - NCT06796062RecruitingPhase 2
Psilocybin for opioid use disorder
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
Albuquerque, New MexicoAges 18–65 - NCT06648642Recruiting
MRI-guided brain stimulation for alcohol use disorder
This study tests whether a new type of brain stimulation, guided by MRI and a robot, can help reduce heavy drinking in people with alcohol use disorder. The treatment is non-invasive and aims to improve brain function related to cravings.
San Antonio, TexasAges 18–65 - NCT06629259RecruitingPhase 2
Guanfacine for Alcohol Use Disorder
This trial tests if guanfacine, a medication that calms certain brain signals, can help people reduce or stop drinking. You may qualify if you have moderate to severe alcohol use disorder and want to quit.
Indianapolis, IndianaAges 18 years+ - NCT06160284RecruitingPhase 1
Psilocybin for brain healing in opioid recovery
This study tests whether psilocybin, a psychedelic substance, can help change brain connections in people recovering from opioid use disorder. It involves brain scans and careful medical monitoring to explore new treatment options.
New Haven, ConnecticutAges 25–55 - NCT05732207Recruiting
Study of brain changes in alcohol use disorder
This study looks at whether alcohol use disorder affects the cerebellum, a part of the brain involved in movement and balance. It may help researchers understand brain impacts and guide better treatments.
Baltimore, MarylandAges 25–55 - NCT06969937RecruitingPhase 2
Ketamine and Neurofeedback for Alcohol Use Disorder
This study tests whether combining ketamine with a brain-training technique called neurofeedback can help people reduce or stop drinking alcohol. It may offer a new treatment option for alcohol use disorder.
ZurichAges 18–65 - NCT06800703Recruiting
Opioid use, pain, and the brain
This study uses brain scans (MRI) to understand how pain affects people with opioid use disorder or regular opioid use, compared to healthy volunteers. It aims to find better ways to treat both pain and opioid addiction.
New Haven, ConnecticutAges 21–60 - NCT06642181RecruitingPhase 1
Guanfacine and meditation with buprenorphine for opioid use disorder
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
Newark, New JerseyAges 18–55 - NCT05913752RecruitingPhase 1/Phase 2
Test drug CMND-100 in people with alcohol use disorder
This early study tests the safety and dosing of CMND-100 in first-time participants, including people with alcohol use disorder (AUD) and some healthy volunteers. It may help researchers understand whether the drug is safe, and how it might affect alcohol use in AUD.
New Haven, ConnecticutAges 18–60 - NCT05613608RecruitingPhase 2/Phase 3
Cannabidiol (CBD) study for alcohol use disorder
This trial tests whether cannabidiol (CBD) can help people cut down or quit drinking alcohol. It enrolls adults diagnosed with alcohol use disorder and wanting to reduce drinking, while checking for safety and other mental health or drug use factors.
Aurora, ColoradoAges 21 years+ - NCT04616781RecruitingPhase 2/Phase 3
Ketone drink study for alcohol use disorder brain function
This study tests whether a ketone-based treatment (a ketone ester) can change brain activity in people with alcohol use disorder who are not currently seeking treatment. You may also have brain scans, so the study is looking for safe MRI eligibility and certain health factors.
Philadelphia, PennsylvaniaAges 21–65 - NCT06837220Recruiting
Smoking cessation program for people in community behavioral health
This study tests a smoking cessation program designed for people who receive care at community behavioral health centers in Chicago. If you're a daily smoker interested in quitting, you may be able to join and get support to help you stop.
Chicago, IllinoisAges 18–26 - NCT06695884Recruiting
Finding the best TMS pulse pattern to boost brain reward activity
This study tests different pulse patterns of transcranial magnetic stimulation (TMS), a noninvasive brain stimulation, to see which one best increases activity in brain reward circuits. It may help people who are dependent on nicotine.
Newark, New JerseyAges 18–55 - NCT06582888RecruitingEarly Phase 1
VR attention test for smoking cravings
This study tests whether a virtual reality (VR) program can measure how your brain pays attention to smoking cues. It also involves taking a medication called varenicline (Chantix) to see if it reduces cravings. You may be eligible if you are a daily smoker, have been smoking for at least 3 years, and are not ready to quit in the next month.
San Diego, CaliforniaAges 22 years+ - NCT05766254Recruiting
Brain stimulation study for nicotine dependence and reward activity
This trial tests different targets for repetitive transcranial magnetic stimulation (rTMS)—a non-surgical brain stimulation—to change brain “reward” activity in people who are nicotine dependent. If you qualify, you may receive sessions of brain stimulation as the researchers look for the best brain target.
Newark, New JerseyAges 18–55 - NCT05932745Recruiting
Test of new e-cig ingredients in current adult users
This study tests how new e-cigarette ingredients affect adults who already use e-cigarettes. You may be asked to avoid tobacco and nicotine briefly before sessions so researchers can measure effects more clearly.
New Haven, ConnecticutAges 18 years+ - NCT05630781Recruiting
Orexin's role in the neurobiology of addiction
This study looks at how a brain chemical called orexin affects addiction. Researchers will give a medication that blocks orexin to see if it helps reduce cravings or use. It might help people who smoke or vape regularly.
Baltimore, MarylandAges 18–60
Hear when a new Nicotine Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nicotine use disorder?
- Yes. Clin2 currently lists 154 recruiting nicotine use disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nicotine use disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nicotine use disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.